PREDICTIVE TEST OF ANTI-TNF ALPHA RESPONSE IN PATIENTS WITH AN INFLAMMATORY DISEASE

    公开(公告)号:US20200165665A1

    公开(公告)日:2020-05-28

    申请号:US16630521

    申请日:2018-07-12

    Abstract: The present invention relates to an ex vivo method for predicting anti-TNF alpha response in a patient with an inflammatory disease in which this treatment is generally indicated, comprising the steps of: a) Measuring, before any anti-TNF alpha treatment, the level LM of Burkholderiales in a patient stool sample, and b) Calculating the score S1=LM/Lref, Wherein: ⋅If S1>1, the patient is considered likely to have a clinical response to an anti-TNF alpha treatment, or; ⋅If S1≤1, the patient is considered unlikely to have a clinical response to an anti-TNF alpha treatment, ⋅Lref being established on patients samples comprising a group (1) of patients with clinical improvement after treatment with TNF-alpha on the one hand, and a group (2) of patients who did not show any clinical improvement after treatment with TNF-alpha on the other hand, each of the groups (1) and (2) comprising at least 60 patients, by measuring the level of Burkholderiales at M0 in each of these groups, and determining the Lref value as the mean value separating patients from group (1) of patients in group (2). It also relates to an ex vivo method for predicting anti-TNF alpha response in a patient with an inflammatory disease in which this treatment is generally indicated, and to the use of at least one bacteria selected from the group comprising Burkholderiales, Serratia marcescens , Klebsiella oxytoca, Enterococcus gallinarum, Weissella cibaria and Coprococcus eutactus, as a predictive biomarker of the clinical outcome of an anti-TNF alpha treatment in an inflammatory disease.

Patent Agency Ranking